Rapid T-cell lymphoma progression associated with immune checkpoint inhibitors

Ohmoto, Akihiro; Fuji, Shigeo

doi:10.1080/17474086.2023.2215424

Cited by 1 publication

(1 citation statement)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In assessing ICI activity in r/r PTCL, investigators unexpectedly saw a subset of patients experience disease hyper-progression, defined as progression within 2 months of treatment initiation, resulting in halting of clinical studies. Small studies have reported rates of hyper-progression as high as 50% while other have been terminated after interim analysis showed futility (46)(47)(48). Thus far, studies evaluating anti-PD-1-based therapy in r/r PTCL (as either monotherapy or in combination) have reported ORRs ranging from 36.4-50% and CRs from 0-35.7% (49)(50)(51).…”

Section: T-cell Lymphomasmentioning

confidence: 99%

Checkpoint inhibition in hematologic malignancies

Tsumura,

Levis,

Tuscano

2023

Front. Oncol.

View full text Add to dashboard Cite

Checkpoint inhibitor therapy has emerged as an effective therapeutic strategy for many types of malignancies, especially in solid tumors. Within the last two decades, numerous monoclonal antibody drugs targeting the CTLA-4 and PD-1/PD-L1 checkpoint pathways have seen FDA approval. Within hematologic malignancies, Hodgkin Lymphoma has seen the greatest clinical benefits thus far with more recent data showing efficacy in the front-line setting. As our understanding of checkpoint inhibition expands, using these pathways as a therapeutic target has shown some utility in the treatment of other hematologic malignancies as well, primarily in the relapsed/refractory settings. Checkpoint inhibition also appears to have a role as a synergistic agent to augment clinical responses to other forms of therapy such as hematopoietic stem cell transplant. Moreover, alternative checkpoint molecules that bypass the well-studied CTLA-4 and PD-1/PD-L1 pathways have emerged as exciting new therapeutic targets. Most excitingly is the use of anti-CD47 blockade in the treatment of high risk MDS and TP-53 mutated AML. Overall, there has been tremendous progress in understanding the benefits of checkpoint inhibition in hematologic malignancies, but further studies are needed in all areas to best utilize these agents. This is a review of the most recent developments and progress in Immune Checkpoint Inhibition in Hematologic Malignancies in the last decade.

show abstract